Skip to content

In the BioHarmony Drug Report Database

Moxetumomab pasudotox

Lumoxiti (moxetumomab pasudotox) is an antibody pharmaceutical. Moxetumomab pasudotox was first approved as Lumoxiti on 2018-09-13. It is used to treat hairy cell leukemia in the USA. The pharmaceutical is active against B-cell receptor CD22.
Trade Name Lumoxiti
Common Name Moxetumomab pasudotox
Indication hairy cell leukemia
Drug Class Monoclonal antibodies
Moxetumomab pasudotox
Get full access now